Trial Profile
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Brexucabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Mantle-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ZUMA-2
- Sponsors Kite Pharma
- 12 Dec 2023 Results indirectly comparing ZUMA-2 and BRUIN trial evaluating unanchored MAIC to estimate the relative treatment effects of these therapies in the post-BTKi setting for R/R MCL, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results of sub-analysis of 27 patients showing predictive performance of MRD measured at months 1, 3, and 6 in estimating relapse potential, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 12 Dec 2023 Results (n=68) assessing an effective treatment in pts with Relapsed and Refractory Post-Btki Mantle Cell Lymphoma with a superior safety profile compared with alloSCT, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.